Pivotal, which specializes in developing and managing clinical trials for the pharmaceutical and biotechnological industry, receives this recognition for the strength of its management model, the quality of its processes, and its commitment to scientific innovation.

Madrid, September 24, 2026 — The Comunidad de Madrid regional government has awarded the Madrid Excelente quality seal to Pivotal, Spain's first CRO (Clinical Research Organisation), in recognition of a management model built on quality, scientific rigor, and innovation. The distinction cements Pivotal's position as one of the leading strategic partners for the Spanish, European, and global pharmaceutical and biotechnological industry.

The seal was presented at Pivotal's headquarters, where Ms Elena Mantilla, CEO of Madrid Excelente, handed the recognition to Dr. Ibrahim Farr, Pivotal´s Chairman & CEO, at an event attended by members of the leadership team and professionals who took part in the evaluation process.

Quality: A Non-Negotiable Requirement in Clinical Research

Pivotal earned the seal after completing the Madrid Excelente evaluation process, which assesses areas such as strategy, ethics and transparency, innovation, customer focus, people management, sustainability, and organisational results.

The evaluation particularly recognised Pivotal's ability to embed quality into every phase of its operations through structured risk management, a strong culture of regulatory compliance, the development of specialised talent, and an operating model that has allowed the company to grow while maintaining high standards in a demanding industry.

"For a company like Pivotal, operating in the demanding environment of clinical research and development, quality is not a differentiator, it's the foundation of everything we do," said Dr. Ibrahim Farr, Founder, Chairman & CEO of Pivotal. "This seal recognises our teams' daily work and certifies, through an independent evaluation process, a model built on scientific rigor, trust, and continuous improvement."

Elena Mantilla, Managing Director of Madrid Excelente, added: "In clinical research and development, trust is built on quality. With Pivotal's addition, one in four companies holding the Madrid Excelente seal now belongs to the health sector, an area that demands the highest quality standards and places innovation, people and patients at the center of its management."

Twenty-Five Years Driving the Development of New Treatments

Founded in 2001, Pivotal brings 25 years of experience in clinical trials development and has taken part in more than 600 studies for the global pharmaceutical and biotechnological companies, with a strong specialisation in oncology, hematology, rare diseases, and advanced therapies.

Headquartered in Madrid, the company employs 220 professionals and runs projects in more than 27 countries across Europe, the Middle East, and the United States, partnering with bio-pharmaceutical companies and research institutions to develop new treatments.

Roughly 70% of Pivotal's business comes from biotechnological companies, with a particularly strong presence in the U.S. market, where it has strengthened its position in recent years. The company continues to expand its international footprint by entering leading clinical research markets, forming strategic alliances, and investing in highly qualified talent and technology solutions for clinical research and development.

The certification is not an endpoint but a milestone in Pivotal's ongoing improvement and growth journey. The company remains committed to maintaining and exceeding the standards behind this recognition, and to continuing to expand its ability to deliver top-tier research services to the patients who need them, and to its clients across Spain and every country in Europe, the Middle East, and North America where it operates.

With this recognition, Pivotal joins the group of organisations distinguished with the Madrid Excelente seal, an accreditation that recognises companies known for the quality of their management and that helps strengthen the Comunidad de Madrid's position as a benchmark in innovation, research, and business development.

About Pivotal

Pivotal was born in 2001 in an environment of scientific excellence and technological innovation. Our founder, Dr. Ibrahim Farr, created it to implement scientific strategies and improve project and data management practices, making clinical trials more efficient and maximising the value of our clients' development programmes. Today, with more than 220 employees and operations in more than 27 countries across Europe, the USA, and the Middle East, we have built expertise across all therapeutic areas and established a center of excellence in innovative therapies and early- and late-phase trials that allows us to tackle our clients' toughest challenges.

After nearly 25 years of hands-on experience and 600 clinical trials, having undergone repeated inspections by international Regulatory Authorities, Pivotal has mastered clinical research and development.

For more information, visit www.pivotalcr.com and follow us on LinkedIn.

About Madrid Excelente

Madrid Excelente is the quality seal of the Comunidad de Madrid, managed by Fundación Madrid, a nonprofit organisation dedicated to boosting the region's business competitiveness. The seal recognises organisations of any sector and size, public or private, that demonstrate a sustained commitment to continuous improvement, innovation, social and environmental responsibility, and customer satisfaction.

The certification model is built on four pillars — purpose, planet, people, and progress — and combines a self-assessment with an external audit carried out by independent certification bodies. The seal is awarded for a three-year period, subject to annual follow-up, and distinguishes organisations that meet demanding standards of management, quality, and operational excellence.

For more information, visit http://www.madridexcelente.com